Asset Details
Do you wish to reserve the book?
Antibody to Influenza Virus Neuraminidase: An Independent Correlate of Protection
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Antibody to Influenza Virus Neuraminidase: An Independent Correlate of Protection
Do you wish to request the book?
Antibody to Influenza Virus Neuraminidase: An Independent Correlate of Protection
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Antibody to Influenza Virus Neuraminidase: An Independent Correlate of Protection
2015
Overview
Background. Laboratory correlates of influenza vaccine protection can best be identified by examining people who are infected despite vaccination. While the importance of antibody to viral hemagglutinin (HA) has long been recognized, the level of protection contributed independently by antibody to viral neuraminidase (NA) has not been determined. Methods. Sera from a controlled trial of the efficacies of inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV) were tested by hemagglutination inhibition (HAI) assay, microneutralization (MN) assay, and a newly standardized lectin-based neuraminidase inhibition (NAI) assay. Results. The NAI assay detected a vaccine response in 37% of IIV recipients, compared with 77% and 67% of participants in whom responses were detected by the HAI and MN assays, respectively. For LAIV recipients, the NAI, HAI, and MN assays detected responses in 6%, 21%, and 17%, respectively. In IIV recipients, as NAI assay titers rose, the frequency of infection fell, similar to patterns seen with HAI and MN assays. HAI and MN assay titers were highly correlated, but NAI assay titers exhibited less of a correlation. Analyses suggested an independent role for NAI antibody in protection, which was similar in the IIV, LAIV, and placebo groups. Conclusions. While NAI antibody is not produced to a large extent in response to current IIV, it appears to have an independent role in protection. As new influenza vaccines are developed, NA content should be considered. Clinical Trials Registration. NCT00538512.
Publisher
Oxford University Press
Subject
/ Adult
/ Antibodies, Viral - biosynthesis
/ Female
/ Hemagglutination Inhibition Tests
/ Hemagglutinins, Viral - immunology
/ Humans
/ Influenza Vaccines - immunology
/ Influenza, Human - immunology
/ Influenza, Human - prevention & control
/ Male
/ Neuraminidase - antagonists & inhibitors
/ Orthomyxoviridae - enzymology
/ Orthomyxoviridae - immunology
/ Vaccines, Attenuated - immunology
/ Vaccines, Inactivated - immunology
/ VIRUSES
